ing may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: firstname.lastname@example.org
or Fordham Financial Management, Inc., 17 Battery Place, South, Suite 643, New York, New York 10004. Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.
This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties, including statements regarding our expectations with respect to the completion, timing and size of our proposed public offering and the application of the
Page: 1 2 3 Related medicine technology :1
|SOURCE Ampio Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock2
. Ampio Pharmaceuticals Announces Proposed Public Offering3
. Ampios CEO and CSO Send Message to Shareholders4
. Four-Time Triathlon World Champion Melanie McQuaid Selects Polar USA as Official Heart Rate Training Solution5
. Ampio Pharmaceuticals Schedules 2012 Update Webcast6
. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California7
. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)8
. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval9
. ResearchMoz.US: Direct to Consumer (DTC) Advertising in Pharmaceuticals - Shift From Traditional Mass-Media Platforms Towards Personalization via Online and Social Media- Market Research Report10
. Cumberland Pharmaceuticals To Announce Second Quarter 2012 Financial Results On August 2, 201211
. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results